Considering our observation that the loss of SOX2 expression leads to a genome-wide reduction in chromatin accessibility and transcription, our results position SOX2 as a central agent in the aberrant activation of gene regulatory pathways that ultimately support a tumor-initiating phenotype in breast and lung adenocarcinomas. The gene discussed is SOX2; the disease is lung adenocarcinoma.